SUTRO BIOPHARMA, INC. (STRO): Results of Operations and Financial Condition
SUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study – Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK
How this was made
The 30-second read
Why it matters
Traders can update STRO’s probability-weighted pipeline outlook based on disclosed Phase 1 safety, response signals, and PK stability, while also factoring in the stated cash runway into at least 2Q 2028.
Market read
Company-specific clinical and financial disclosures can move clinical-stage biotech positioning, especially for ADC investors focused on safety, PK stability, and early response signals.
What to watch
The filing notes optimization between 4 and 5 mg/kg and that the maximum tolerated dose is not yet defined, so near-term upside may be capped until expansion cohorts confirm RECIST-evaluable durability.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and an early clinical update for Sutro’s lead ADC program STRO-004, plus pipeline timing for STRO-006 and STRO-227 and collaboration progress with Astellas.
Ticker impact
Sutro reports Q2 2026 results and early Phase 1 STRO-004 data, including confirmed and ongoing partial responses plus favorable tolerability and PK.
Likely positive bias for STRO into upcoming clinical readouts, with volatility tied to dose-escalation outcomes and next updates in 1H 2027.
The filing discloses specific early safety, response signals, PK stability, and a balance-sheet cash figure ($164.3M) supporting operations into at least 2Q 2028, which can re-rate probability-weighted outcomes. However, it is still Phase 1 and the maximum tolerated dose is not yet defined, limiting conviction on magnitude.
Market effects
Adds incremental evidence for next-generation ADC design differentiation (DAR8 stability, lower free payload) within oncology ADC peers.
Limited, mostly US biotech sentiment and risk-on/off for clinical-stage oncology names.
Low, primarily company-specific clinical and financing runway information.
Counterpoint
Early partial responses and low discontinuation do not guarantee efficacy; target-related AEs and DLTs at the highest dose level suggest a narrower therapeutic window than hoped.
Key entities
- companySutro Biopharma, Inc.
Clinical-stage oncology company reporting Q2 2026 results and early Phase 1 STRO-004 data, with pipeline and cash runway updates.
- clinical_programSTRO-004 (STR IV E-01)
TF-targeting DAR8 exatecan ADC Phase 1 study reporting early partial responses, tolerability, and dose-optimization between 4 and 5 mg/kg.
- collaboration_partnerAstellas
Collaboration partner progressing two dual-payload iADC programs; Sutro received a $10M milestone in April 2026 and expects the second program to enter the clinic by end of 2026.
